Premium
Switch to atovaquone and subsequent re‐challenge with trimethoprim‐sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population
Author(s) -
McLaughlin Milena M.,
Galal Audrey,
Richardson Chad L.,
Sutton Sarah H.,
Barr Viktorija O.,
Patel Niketa,
Mitchell Porntiwa,
Stosor Valentina
Publication year - 2017
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12769
Subject(s) - medicine , sulfamethoxazole , trimethoprim , atovaquone , kidney transplant , population , adverse effect , pneumocystis pneumonia , pneumonia , kidney transplantation , kidney , pneumocystis jirovecii , immunology , antibiotics , malaria , microbiology and biotechnology , environmental health , plasmodium falciparum , biology
Kidney transplant recipients who are switched to atovaquone ( ATO ) from trimethoprim‐sulfamethoxazole ( TMP / SMX ) for Pneumocystis jirovecii pneumonia ( PJP ) prophylaxis because of adverse events or complications may miss opportunities to be re‐challenged with TMP / SMX , the first‐line agent. This single‐site, retrospective study assessed kidney transplant recipients for documented reasons for switching from TMP / SMX to alternate PJP prophylaxis and outcomes of TMP / SMX re‐challenge. Out of 166 patients, 155 initially received TMP / SMX ; of these, 31 were switched to ATO for various reasons. Fourteen patients receiving ATO were re‐challenged with TMP / SMX ; all were successfully re‐initiated on TMP / SMX therapy. Most patients switched to ATO post kidney transplant secondary to non‐hypersensitivity reasons should be re‐challenged with TMP / SMX because of the advantages it provides over other agents.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom